Immunovant Sector: Pharmaceuticals and biotechnology (autoimmune and immunology therapeutics) HQ: 320 W 37th St., New York, NY Year Founded: 2018 Key Leaders: Eric Venker, MD, PharmD, CEO Number of Employees: 362 Stage: Public Financial Snapshot: $3.83 billion Notable Investors: SG Americas Securities, Roivant Sciences, RTW Investments, and BVF Partners Key Products: Immunovant is developing Batoclimab, an FcRn-targeting monoclonal antibody for autoimmune diseases (MG, TED, Graves disease), which is in Phase 3 registrational trials
The goal of weight loss should never be just be smaller. The goal is to be healthier, stronger, and metabolically resilient
Eating protein-rich foods and staying hydrated amplify semaglutide's fullness effect, because protein triggers its own satiety hormones and slows gastric emptying alongside the medication
Panserat, S
Metabolic Set Point Has Not Fully Stabilized Your body has a natural tendency to defend a certain weight range
Melanotan-2# Melanotan-2 is a cyclic heptapeptide with a lactam bridge that increases metabolic stability
